Chikungunya Virus-Like Particles as Vaccine Candidates: A Pilot Study
9781774695296
pages
Arcler Education Inc
Overview
Chikungunya Virus VLP (Virus-Like Particle) is a unique product that has been developed in response to the need for high purity, properly assembled and glycosylated Chikungunya virus antigens for use in the development of Chikungunya virus diagnostics and in vaccine development and R&D. This book presents main emphasis continues to be the Chikungunya virus for virology interests, although they have been described in specific cases where more is known about the mechanism of Chikungunya virus replication. The chapters have been organized in such a way that they provide sequential knowledge. Chikungunya virus (CHIKV) has now emerged as one of the most important arbovirus of public health significance. Infection of CHIKV in humans is characterized by rash, high fever and severe arthritis that may persist for years.
Author Bio
Dr. Shweta Saraswat is currently working as an Assistant Professor at the Amity Institute of Virology and Immunology (AIVI), Amity University, Uttar Pradesh, Noida, India. Dr. Saraswat has 3 years of teaching experience and more than 10 years of research experience. She is a graduate and has a master's in microbiology from Jiwaji University, Gwalior. Dr. Saraswat completed her doctorate in Biological Sciences (Virology) from Bharathiar University, Coimbatore. Her research area was the development of Chikungunya Virus-Like particles using Picha pastoris. She worked in various renowned organizations in India. She worked at the Defence Research and Development Establishment (DRDE), Gwalior as a research fellow. Here, her area of expertise was the development of diagnostics and prophylactics against Chikungunya, Dengue, and Swine flu viruses. She was a postdoctoral fellow at Shiv Nadar University, Gautam Buddha Nagar. Her work was mainly focused on the "Mapping of cleavage site of HEV ORF1 expressed using the Baculovirus expression system". After that, she worked as a scientist at the Translational Health Science and Technology Institute (THSTI), Faridabad, to isolate various DENV isolates using clinical samples. She also identified some small molecule inhibitors against DENV as well as other flaviviruses. At the National Institute of Immunology, her focus was to develop neutralization assays for different JEV isolates. She has been awarded by various reputed agencies. She has received DST-NPDF and DHR-young scientist national awards. She also got an international travel grant from the International Conference on Antiviral Research (ICAR). She also submitted many DENV gene sequences to NCBI Pubmed. Dr. Saraswat has published several research papers in international journals. She is the author and co-author of so many international journals. She is also a review editor for Frontiers in Cellular and Infection Microbiology.
